Myrtenol is a bicyclic monoterpene alcohol found in smaller amounts across pinene-rich essential oils and has a larger standalone preclinical literature than many archive constituents. The strongest live evidence supports its chemical identity, its role as a minor oxygenated monoterpene in oils such as hyssop and galbanum, and several rat studies reporting anti-inflammatory and antioxidant effects in disease models. Those findings remain preclinical, so AromaForge should frame myrtenol as an emerging mechanism-rich constituent rather than a clinically validated active.
Chemical identity and composition
PubChem classifies myrtenol as a bicyclic monoterpene alcohol with formula C10H16O. It is structurally related to pinene oxidation products and is often discussed alongside myrtenal and myrtenyl esters in flavor and fragrance safety evaluations.
Aroma and practical use
- Use the recorded piney, fresh, woody, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2019 allergic-asthma rat study reported that intraperitoneal myrtenol lowered IL-1beta, TNF-alpha, and malondialdehyde while increasing IL-10 and glutathione peroxidase activity relative to untreated asthma controls.
A 2019 allergic-asthma rat study reported that intraperitoneal myrtenol lowered IL-1beta, TNF-alpha, and malondialdehyde while increasing IL-10 and glutathione peroxidase activity relative to untreated asthma controls.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2024 inhalation study in asthmatic rats found that myrtenol improved spatial learning, memory, long-term potentiation, and anxiety-like behavior while lowering hippocampal IL-1beta and NF-kB and increasing BDNF.
A 2024 inhalation study in asthmatic rats found that myrtenol improved spatial learning, memory, long-term potentiation, and anxiety-like behavior while lowering hippocampal IL-1beta and NF-kB and increasing BDNF.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 MCAO rat study reported improved neurological scores, reduced edema and apoptosis markers, and increased VEGF and FGF2 after myrtenol, with ERK1/2 inhibition reversing the benefit.
A 2021 MCAO rat study reported improved neurological scores, reduced edema and apoptosis markers, and increased VEGF and FGF2 after myrtenol, with ERK1/2 inhibition reversing the benefit.
This experimental finding does not establish benefit, dose or safety in people using this blend.
An EFSA flavoring-group evaluation concluded that the concern for genotoxicity could be ruled out for myrtenol within the reviewed flavoring context.
An EFSA flavoring-group evaluation concluded that the concern for genotoxicity could be ruled out for myrtenol within the reviewed flavoring context.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedEFSA's FGE.208 revision history places myrtenol among the related flavoring substances for which the reviewed genotoxicity concern was ruled out, but that is not the same as a broad topical-use endorsement for all contexts.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The accessible public evidence base is preclinical; a constituent-specific human clinical efficacy literature for isolated myrtenol was not verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
NF-kB-linked inflammation suppression
Recent rat work reported lower hippocampal NF-kB expression and IL-1beta after inhaled myrtenol in an allergic-asthma model, consistent with an anti-inflammatory mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
ERK1/2 pathway activation in cerebral ischemia model
A cerebral ischemia-reperfusion study found that myrtenol's protective effects were reversed by the ERK1/2 inhibitor U0126, supporting pathway involvement in that model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
redox-balancing antioxidant effect
Multiple rat studies reported lower malondialdehyde and higher endogenous antioxidant enzyme activity after myrtenol exposure, supporting a recurring oxidative-stress modulation signal.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical trial focused on isolated myrtenol was verified in this pass.
- Public constituent-specific dermal restriction data for myrtenol were not verified.
- The direct mechanism literature remains model-specific and preclinical rather than translational.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.